Narcis-Georges Manolache1, Georges Mjaess1, Romain Diamand2, Simone Albisinni1, Thierry Roumeguère3. 1. Département d'urologie, hôpital Érasme, hôpital universitaire de Bruxelles, Bruxelles, Belgique. 2. Département d'urologie, institut Jules Bordet, hôpital universitaire de Bruxelles, Bruxelles, Belgique. 3. Département d'urologie, hôpital Érasme, hôpital universitaire de Bruxelles, Bruxelles, Belgique; Département d'urologie, institut Jules Bordet, hôpital universitaire de Bruxelles, Bruxelles, Belgique. Electronic address: thierry.roumeguere@erasme.ulb.ac.be.
Abstract
INTRODUCTION: Male gender has been shown to be a risk factor for COVID-19 infection, and men are more likely to develop severe disease. The aim of this study was to evaluate the effect of androgen deprivation therapy (ADT) on the incidence of infection and severity of SARS-CoV-2 in prostate cancer patients. METHODS: A systematic review and meta-analysis were performed after searching PubMed, Scopus, and ClinicalTrial.org databases, between January 2020 and March 2022. Analyses were interpreted through forest plots for the following parameters: risk of infection, hospitalization, intensive care admission, and SARS-CoV-2-related death, with random or fixed-effects models. RESULTS: Fifteen articles were included in the systematic review and ten in the meta-analysis. Seven studies evaluated risk of infection in patients on ADT: OR=1.11 (95 % IC : [0.48-2.58] ; P=0.81). Six studies evaluated the risk of hospitalization in patients on ADT: TDA : OR=1.58 (95 % IC : [0.94-2.64] ; P=0.08). Seven studies evaluated risk of ICU admission in patients on ADT: OR=0.90 (95 % IC : [0.71-1.13] ; P=0.37). Nine studies evaluated mortality risk in patients on ADT: OR=1.07 (95 % IC : [0.61-1.87] ; P=0.82). CONCLUSION: ADT does not protect against SARS-CoV-2 in prostate cancer patients, nor does it protect against hospitalization, ICU admission, or mortality. These results remain questionable given the retrospective nature of the majority of studies included in our meta-analysis.
INTRODUCTION: Male gender has been shown to be a risk factor for COVID-19 infection, and men are more likely to develop severe disease. The aim of this study was to evaluate the effect of androgen deprivation therapy (ADT) on the incidence of infection and severity of SARS-CoV-2 in prostate cancer patients. METHODS: A systematic review and meta-analysis were performed after searching PubMed, Scopus, and ClinicalTrial.org databases, between January 2020 and March 2022. Analyses were interpreted through forest plots for the following parameters: risk of infection, hospitalization, intensive care admission, and SARS-CoV-2-related death, with random or fixed-effects models. RESULTS: Fifteen articles were included in the systematic review and ten in the meta-analysis. Seven studies evaluated risk of infection in patients on ADT: OR=1.11 (95 % IC : [0.48-2.58] ; P=0.81). Six studies evaluated the risk of hospitalization in patients on ADT: TDA : OR=1.58 (95 % IC : [0.94-2.64] ; P=0.08). Seven studies evaluated risk of ICU admission in patients on ADT: OR=0.90 (95 % IC : [0.71-1.13] ; P=0.37). Nine studies evaluated mortality risk in patients on ADT: OR=1.07 (95 % IC : [0.61-1.87] ; P=0.82). CONCLUSION: ADT does not protect against SARS-CoV-2 in prostate cancer patients, nor does it protect against hospitalization, ICU admission, or mortality. These results remain questionable given the retrospective nature of the majority of studies included in our meta-analysis.
Authors: Giacomo Grasselli; Alberto Zangrillo; Alberto Zanella; Massimo Antonelli; Luca Cabrini; Antonio Castelli; Danilo Cereda; Antonio Coluccello; Giuseppe Foti; Roberto Fumagalli; Giorgio Iotti; Nicola Latronico; Luca Lorini; Stefano Merler; Giuseppe Natalini; Alessandra Piatti; Marco Vito Ranieri; Anna Mara Scandroglio; Enrico Storti; Maurizio Cecconi; Antonio Pesenti Journal: JAMA Date: 2020-04-28 Impact factor: 56.272
Authors: M Montopoli; S Zumerle; R Vettor; M Rugge; M Zorzi; C V Catapano; G M Carbone; A Cavalli; F Pagano; E Ragazzi; T Prayer-Galetti; A Alimonti Journal: Ann Oncol Date: 2020-05-06 Impact factor: 32.976
Authors: Flavio A Cadegiani; John McCoy; Carlos Gustavo Wambier; Sergio Vaño-Galván; Jerry Shapiro; Antonella Tosti; Ricardo A Zimerman; Andy Goren Journal: Cureus Date: 2021-02-22
Authors: Karin Welén; Ebba Rosendal; Magnus Gisslén; Annasara Lenman; Eva Freyhult; Osvaldo Fonseca-Rodríguez; Daniel Bremell; Johan Stranne; Åse Östholm Balkhed; Katarina Niward; Johanna Repo; David Robinsson; Anna J Henningsson; Johan Styrke; Martin Angelin; Elisabeth Lindquist; Annika Allard; Miriam Becker; Stina Rudolfsson; Robert Buckland; Camilla Thellenberg Carlsson; Anders Bjartell; Anna C Nilsson; Clas Ahlm; Anne-Marie Fors Connolly; Anna K Överby; Andreas Josefsson Journal: Eur Urol Date: 2021-12-15 Impact factor: 20.096